circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Ling, Yun; Liang, Gehao; Lin, Qun; Fang, Xiaolin; Luo, Qing; Cen, Yinghuan; Mehrpour, Maryam; Hamaï, Ahmed; Liu, Zihao; Shi, Yu; Li, Juanmei; Lin, Wanyi; Jia, Shiguo; Yang, Wenqian; Liu, Qiang; Song, Erwei; Li, Jun; Gong, Chang

doi:10.1186/s12943-021-01476-7

Cited by 52 publications

(29 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The circRNAs with circular loop structures are originated from pre-mature RNA by back-splicing and represent a widespread class of non-coding RNAs that are recently found to have regulatory effect on the MDR in cancers 117 . The circRNAs can bind chromosome and generate RNS–DNA hybrids which pause transcription procedure 118 , 119 .…”

Section: Mechanisms For Regulation Of the Mdr-associated Factors Or S...mentioning

confidence: 99%

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Zhang

Ye²,

Chen³

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Mechanisms For Regulation Of the Mdr-associated Factors Or S...mentioning

confidence: 99%

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Zhang

Ye²,

Chen³

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…circCDYL2 plays a role in the formation of the GRB7-FAK complex. The circCDYL2-GRB7-FAK complex plays a critical role in maintaining the HER2 signal and contributes to TRA resistance [107]. Li et al reported that hsa_circ_0001598 is an oncogenic circRNA that plays a vital role in regulating PD-L1 expression and results in the immune escape and resistance of TRA in BC [108].…”

Section: Other Drugsmentioning

confidence: 99%

circRNAs in drug resistance of breast cancer

Mısır¹,

YAMAN²,

PETROVIĆ³

et al. 2022

Oncology Research

View full text Add to dashboard Cite

Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment.Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends.Accumulating evidence suggests that circRNAs have a vital role in cancer development, progression, and BC resistance to chemotherapy. The purpose of this review is to discuss the biological properties of circRNAs, and how circRNAs induce resistance to conventional therapeutic anti-cancer drugs used in BC treatment, by emphasizing and summarizing the potential roles of circRNAs in mechanisms of drug resistance, such as drug efflux, apoptosis dysfunction, autophagy, and DNA damage repair. CircRNAs are associated with drug resistance via ATP-binding cassette (ABC) efflux transporters, while some others by inhibition of cell apoptosis, thus leading to resistance to tamoxifen in BC cells. In contrast, others are involved in the promotion of BC cells chemoresistance by doxorubicininduced autophagy. CircRNAs may have clinical significance in regulating or overcoming BC drug resistance and may give directions towards a novel approach to personalized BC treatment. CircRNAs may significantly contribute to the identification of new therapeutic targets for the prevention of BC chemoresistance.

show abstract

“…(PD-L1) mediated immune escape and trastuzumab resistance by circ_0001598/miR-1184/PD-L1 axis [73]. More recently, Ling et al [74] found that circCDYL2 was up-regulated in trastuzumab-resistant BC tissues and cells, indicating its potential role in trastuzumab resistance.…”

Section: The Dysregulation Of Circrnas Is Related To Drug Resistance ...mentioning

confidence: 99%

Circular RNAs: novel regulators of resistance to systemic treatments in breast cancer

Guo¹,

Hua²

2022

neo

View full text Add to dashboard Cite

Systematic treatments including chemotherapy, endocrine therapy, and HER2-targeted therapy are important therapeutic approaches to breast cancer. However, drug resistance is a major barrier to achieving cure in breast cancer (BC) patients. Hence, it is urgent to gain insight into the drug-resistance mechanisms in order to improve the prognosis of BC patients. Genetic alternations, epigenetic alternations, and other non-genetic mechanisms such as BC stem-like cells, metabolic reprogramming, and tumor microenvironment contribute to drug resistance of BC. With the development of single-cell sequencing of circulating tumor cell and next-generation sequencing of matched pre-and post-progression tumor biopsies or ctDNA from BC patients with drug resistance, new mechanisms of resistance are being discovered. An increasing number of microRNAs and long non-coding RNAs have been found to be associated with the drug resistance of BC. However, there are few reports on the role of circular RNAs (circRNAs) as master regulators of drug resistance.Therefore, there is still much to say in the field of drug resistance-related circRNAs. In this review, we mainly focus on literature evidence for the detailed mechanisms associated with systematic expression of tumor suppressive circRNAs or knockdown of oncogenic circRNAs has been verified to reverse drug resistance of BC cells, which highlights that circRNAs may function as potential biomarkers and/or therapeutic targets of BC. Treatment targeting abnormally expressed circRNAs alone or combined with other systemic treatments may be a promising approach to conquering drug resistance.

show abstract

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Cited by 52 publications

References 46 publications

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

circRNAs in drug resistance of breast cancer

Circular RNAs: novel regulators of resistance to systemic treatments in breast cancer

Contact Info

Product

Resources

About